Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Moderna
MRNA
|
$1.79B |
| 2 |
Illumina
ILMN
|
$780M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$727M |
| 4 |
DexCom
DXCM
|
$453M |
| 5 |
Netflix
NFLX
|
$384M |
Top Sells
| 1 |
Tesla
TSLA
|
$5.22B |
| 2 |
Amazon
AMZN
|
$1.3B |
| 3 |
Alphabet (Google) Class C
GOOG
|
$610M |
| 4 |
Zillow
Z
|
$470M |
| 5 |
Ionis Pharmaceuticals
IONS
|
$271M |
Sector Composition
| 1 | Consumer Discretionary | 37.93% |
| 2 | Technology | 16.18% |
| 3 | Healthcare | 15.43% |
| 4 | Communication Services | 14.41% |
| 5 | Financials | 5.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
McDonald's
MCD
$226B
| $38M | 0.02% |
177,176
-5
| -0% | -$1.07K |
|
177
Sutro Biopharma
STRO
$86.5M
| $36.8M | 0.02% |
1,695,654
| – | – |
|
|
BNR
178
Burning Rock Biotech
BNR
$91.2M
| $36.4M | 0.02% |
157,756
+56,529
| +56% | +$13.1M |
|
179
Digimarc
DMRC
$175M
| $35.9M | 0.02% |
760,625
-773
| -0.1% | -$36.5K |
|
|
RUBY
180
DELISTED
Rubius Therapeutics, Inc
RUBY
| $35.7M | 0.02% |
4,710,061
+436,200
| +10% | +$3.31M |
|
181
Ares Capital
ARCC
$15.8B
| $31.8M | 0.02% |
1,880,870
| – | – |
|
|
TRHC
182
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $31.6M | 0.02% |
738,793
+73,642
| +11% | +$3.15M |
|
183
iQIYI
IQ
$2.61B
| $31.6M | 0.02% |
1,809,256
+667,046
| +58% | +$11.7M |
|
|
FARO
184
DELISTED
Faro Technologies
FARO
| $31.5M | 0.02% |
446,108
+2,553
| +0.6% | +$180K |
|
185
Dolby
DLB
$6.96B
| $28.5M | 0.02% |
293,157
+3,317
| +1% | +$322K |
|
186
Tandem Diabetes Care
TNDM
$835M
| $28.3M | 0.02% |
295,445
+176
| +0.1% | +$16.8K |
|
187
Silicon Motion
SIMO
$2.74B
| $28M | 0.02% |
+581,441
| New | +$28M |
|
188
Cisco
CSCO
$269B
| $27.3M | 0.02% |
610,056
-1,613
| -0.3% | -$72.2K |
|
189
T Rowe Price
TROW
$24.5B
| $26.9M | 0.02% |
177,441
-178
| -0.1% | -$26.9K |
|
190
Edwards Lifesciences
EW
$47.5B
| $25.6M | 0.01% |
280,311
+26,830
| +11% | +$2.45M |
|
191
Medtronic
MDT
$119B
| $24.5M | 0.01% |
208,747
-140
| -0.1% | -$16.4K |
|
192
Bilibili
BILI
$9.28B
| $24.2M | 0.01% |
282,426
+141,515
| +100% | +$12.1M |
|
193
Veeco
VECO
$1.44B
| $23.2M | 0.01% |
1,333,700
+14,041
| +1% | +$244K |
|
|
NBTX
194
Nanobiotix
NBTX
$408M
| $23.1M | 0.01% |
+1,400,000
| New | +$23.1M |
|
195
Waters Corp
WAT
$17.8B
| $23M | 0.01% |
93,091
-9,374
| -9% | -$2.32M |
|
196
CEVA Inc
CEVA
$528M
| $22.1M | 0.01% |
486,512
+1,057
| +0.2% | +$48.1K |
|
|
SIX
197
DELISTED
Six Flags Entertainment Corp.
SIX
| $21.6M | 0.01% |
+634,800
| New | +$21.6M |
|
198
Cullen/Frost Bankers
CFR
$8.33B
| $20.9M | 0.01% |
239,337
+9,253
| +4% | +$807K |
|
199
Axogen
AXGN
$712M
| $20.8M | 0.01% |
1,161,752
+81,068
| +8% | +$1.45M |
|
200
HEICO
HEI
$44.8B
| $20.8M | 0.01% |
157,048
-5,800
| -4% | -$768K |
|